Brief: Can-Fite Completes Patient Enrollment In Phase 2A Pancreatic Cancer Study Of Namodenoson
20/01/2026 12:38
Jan 20 (Reuters) - Can Fite Biopharma Ltd CANF.TA: CAN-FITE COMPLETES PATIENT ENROLLMENT IN PHASE 2A PANCREATIC CANCER STUDY OF NAMODENOSON CAN FITE BIOPHARMA LTD: PRIMARY SAFETY ENDPOINT DEMONSTRATED TO DATE; TOP-LINE EFFICACY DATA EXPECTED IN Q3 2026 Source text: ID:nGNXbhKJ5d Further company coverage: CANF.TA (Reporting by Kunal Das) ((Kunal.Das2@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Following Positive Phase 2A Pancreatic Cancer Data, Can-Fite Advances Namodenoson Into Phase 2B Combination Study With Immunotherapy
Can-Fite Biopharma surges as pancreatic cancer drug meets main goal in study
Brief: Can-Fite Completes Patient Enrollment In Phase 2A Pancreatic Cancer Study Of Namodenoson
Board Approved A 1-For-3,000 Reverse Split Of Company's Ordinary Shares
Brief: Can-Fite Provides Update On Clinical And Financial Status